An accelerated aging study is a stress test on packaging, not a demonstration that sterile contents will still be sterile years from now, and the difference decides how a clinic should read the expiry date on a pouch. The governing guide, ASTM F1980-21, says it directly: accelerated and real-time aging verify "the time-related aspects of potential integrity loss only". What the study buys is a defensible expiry date before real-time data exists — and the same standard says that date stays tentative until real-time results arrive.
This matters when a clinic is choosing between packaging formats, when a supplier's technical file is being reviewed before a switch, or when an auditor asks what the expiry date on the box is actually based on. The pouch in the drawer is the visible end of a chain that runs from the packaging standard, through an aging protocol, to a test report nobody at the clinic has seen. This guide explains what that report can carry, what it cannot, and which fields to ask for. Clinics that want a packaging format with a documented Class 4 indicator and a lot number that ties back to the report are usually looking at something like these Class 4 self-sealing sterilization pouches — 200 per box.
What does an aging study actually measure?
An aging study measures the effect of time on the sterile barrier system: the materials, the seals, the adhesive bonds and the cohesive strength that hold a package closed. ASTM F1980-21 explains the mechanism in its significance section — loss of sterile barrier system integrity may occur as a result of physical properties of the materials and adhesive or cohesive bonds degrading over time, or by subsequent dynamic events during shipping and handling, or both. The guide's scope is equally specific about what it does not cover: distribution, handling and shipping events belong to package performance testing, and real-time aging protocols are not addressed in the guide at all.
That boundary is the first thing to hold on to. An aging report is evidence about degradation over time. It is not evidence that a package survived a pallet drop, and it is not evidence that a sterilization cycle achieved a stated sterility assurance level — those are separate claims with separate test methods. A clinic that conflates them will over-read one document and under-ask for the others.
How is accelerated time calculated?
The arithmetic is a temperature-accelerated equivalence. ASTM F1980-21 directs that conservative accelerated aging factors (AAFs) must be used when little is known about the sterile barrier system material being evaluated, and that more aggressive factors may be used only with documented evidence showing a correlation between real-time and accelerated results. The factor is conventionally expressed with a Q10 value — the multiplier for a 10 °C increase — so that the equivalent aging time is the claimed shelf life divided by the factor:
AAF = Q10^((T_aging − T_storage) / 10) and accelerated time = claimed shelf life ÷ AAF
With the commonly used conservative value of Q10 = 2, storage at 23 °C and aging at 50 °C gives a factor of 2^2.7 ≈ 6.5, so a year of shelf life is modelled in about eight weeks. The figures below are arithmetic from that formula, not values quoted from a standard, and they are shown so the shape of the trade-off is visible:
| Claimed shelf life | Storage at 23 °C, aging at 50 °C, Q10 = 2 | Aging time needed |
|---|---|---|
| 1 year | AAF ≈ 6.5 | ≈ 56 days |
| 2 years | AAF ≈ 6.5 | ≈ 112 days |
| 3 years | AAF ≈ 6.5 | ≈ 169 days |
| 5 years | AAF ≈ 6.5 | ≈ 281 days |
The published converter example from a packaging manufacturer lands in the same place, which is a useful cross-check that the convention is being applied consistently: Nelipak's explanation of its own F1980-based testing states that a product normally stored at 23 °C and aged at 50 °C is equivalent to a year of aging after 57 days, or five years after 281 days. If a supplier's report shows a five-year claim built on a much shorter exposure, the Q10 value and the temperatures are the first things to reconcile — a larger Q10 or a hotter chamber shortens the calendar without changing the underlying conservatism, and F1980-21 requires the choice to be documented.
What can an accelerated aging report support?
Published standards are unusually explicit here, and the wording is worth reading rather than paraphrasing. ISO 11607-1:2019 requires that stability testing demonstrate that the sterile barrier system maintains integrity over time, and its stability clause states that "stability testing, using accelerated aging protocols, shall be regarded as sufficient evidence for claimed expiry dates until data from real-time aging studies are available" — a sentence ASTM F1980-21 quotes in full in its own significance section. F1980-21's scope repeats the position: information obtained using the guide may be regarded as sufficient evidence for expiration date claims for medical devices and sterile barrier systems until data from real-time aging studies are available.
| The report can support | The report cannot support |
|---|---|
| A claimed shelf life on the label, for the packaged configuration tested | Any inference about how the package behaves after shipping, drop or compression events |
| A statement about time-related loss of seal and material integrity | A statement about the sterilization process, its parameters, or sterility assurance |
| Screening for aging-related failure mechanisms before market launch | Any conclusion about storage conditions the product is allowed to be kept in |
| A conditional expiry date while real-time data accumulates | A permanent expiry date, once real-time data becomes available |
| Comparability between design iterations of the same package | Equivalence between two different materials with no correlation data |
Two rows in that right-hand column come straight from the guide. F1980-21 states that data obtained from accelerated aging studies is not to be used as a manner of establishing label storage conditions for sterile barrier systems, so a clinic cannot read "aged at 50 °C" as permission to store stock in a warm room. And it states that the resulting expiry date is based on a conservative estimate of the aging factor and is tentative until real-time aging studies are completed on the sterile barrier system. The date on the box is therefore most sensibly read as a conditional claim with a countdown attached.
When is real-time aging unavoidable?
The guide is blunt about the relationship between the two programmes: to ensure that accelerated aging studies represent real-time effects, real-time aging studies must be conducted in parallel to accelerated studies, and real-time studies must be carried out to the claimed shelf life and performed to their completion. F1980-21 also notes that real-time aging is the requirement of ISO 11607-1:2019, with accelerated aging serving as the interim evidence that lets a product reach the market first.
Testing laboratories phrase the same division in operational terms, and it is worth knowing how they phrase it because it is what you will hear when you ask for a report. Nelson Labs describes accelerated aging as the simulation step and states that real-time aging is required when establishing an expiration date for a product or its packaging. In practice a clinic sees four situations where real-time data is the deciding evidence rather than the supporting evidence:
- A material family the supplier has no prior correlation data for, where F1980-21 requires a conservative factor rather than an aggressive one.
- A claim long enough that the accelerated exposure needed to support it becomes physically awkward, at which point the real-time run is doing the real work.
- A packaging change — new film, new coating, new seal pattern — where the correlation between accelerated and real-time results has to be re-established rather than assumed.
- An audit or tender question that asks for real-time data on the specific product, not for a method statement.
Which fields should a clinic ask for in a supplier aging report?
Most clinics never see the full report, and most do not need to. What a clinic does need is enough of it to know whether the expiry date is being supported the way the standards describe. These are the fields worth requesting, and the reason each one matters:
| Field | Why it decides the answer |
|---|---|
| Standard and edition followed (ASTM F1980-21, ISO 11607-1:2019) | Establishes which acceptance criteria the study was built against |
| Aging temperature, tolerance and chamber humidity | The AAF is meaningless without the actual exposure conditions |
| Q10 value used, and the justification for it | Separates a conservative factor from an aggressive one |
| Accelerated duration per timepoint and the shelf life claimed | Lets you reproduce the arithmetic above |
| Sample configuration, including the worst-case device load | A pouch aged empty is not evidence for a pouch aged with an instrument set |
| Test methods applied after aging (seal strength, dye penetration, bubble emission, visual) | Determines what "integrity" meant in that study |
| Acceptance criteria and any failures | A report with no failures usually means no criteria were stated |
| Real-time study start date and current status | Shows whether the conditional date is being converted into a permanent one |
| Report author, laboratory and date | Identifies who is accountable for the result |
| Whether the packaging process itself was validated separately | Aging validates the package over time; the sealing process needs its own validation record |
The last row is the one clinics most often miss, and it is a scope question rather than an aging question. ISO 11607-2:2019 specifies requirements for the development and validation of processes for packaging terminally sterilized medical devices, including forming, sealing and assembly, and it applies to health care facilities as well as to industry. Aging evidence and sealing-process validation are two different documents covering two different risks, and a supplier who can produce one but not the other has not finished the file.
What should a clinic do with the date on the box?
Three habits follow from the standards rather than from any one supplier's practice. Keep the stock in its original carton inside the storage conditions the manufacturer states, because the expiry date was generated against those conditions and F1980-21 explicitly refuses to let accelerated data define them. Treat a packaging change as a project rather than a purchase order: a new film or seal pattern changes the material under study, and the validation work belongs to whoever manufactures the package. And keep the packaging lot number with the load record, because the expiry date is a property of a lot, not of a product line — the same reason monitoring records carry indicator lots. Clinics that wrap rather than pouch face the same question with a different format, which is why the roll specification matters as much as the film: a sterilization roll — 76 mm × 50 m, heat-seal, Class 1 indicator ages as a system with its own seals, not as a length of material.
For the surrounding paperwork, the sterilization compliance hub collects the storage, monitoring and record-keeping requirements in one place, the compliance log centre covers the record side, and clinics that are comparing packaging formats across several sites usually start from the wholesale and institutional route. Where the question is specific to a single practice's storage setup, a compliance review conversation is faster than working through a template. Reselling? become a distributor.
Related reading
- Accelerated aging and distribution testing: F1980 and D4169 covers the transport side of the same claim, which this article deliberately leaves aside.
- ISO 11607-1 versus ISO 11607-2 separates materials and sterile barrier systems from the validation of forming and sealing processes.
- Sterile storage shelf life in Canada and the United States explains which rule sets the date a clinic actually prints on a label.
- How should sterilization pouches be stored turns the storage conditions into practice.
Frequently Asked Questions
Does an accelerated aging report prove the product is sterile at the expiry date?
No. It provides evidence that the sterile barrier system maintains integrity over time, which is a precondition for sterility being maintained, and both ASTM F1980-21 and ISO 11607-1:2019 treat it as sufficient evidence for a claimed expiry date only until real-time data is available. Sterility of the contents comes from the validated sterilization process, not from the aging study.
Can a supplier claim a five-year shelf life from a few months of testing?
That is the normal shape of an accelerated study: the exposure is shorter than the claim because the aging factor multiplies it. What has to be documented is the temperature, the Q10 value used and the justification for that value, because F1980-21 requires conservative factors where little is known about the materials. A five-year claim from a very short exposure is not automatically wrong, but the arithmetic has to hold and the factor has to be defensible.
What does it mean that the expiry date is "tentative"?
ASTM F1980-21 states that the resulting expiry date is based on a conservative estimate of the aging factor and is tentative until real-time aging studies are completed on the sterile barrier system. In use, that means the date is valid and defensible, and it will be re-confirmed or revised when the parallel real-time study reaches its endpoints.
Does accelerated aging tell me how to store the stock?
No, and the standard rules this out explicitly: data from accelerated aging studies is not to be used to establish label storage conditions. Store to the manufacturer's stated conditions and keep the packaging in its carton, because the study does not model humidity or temperature excursions in your storage room.
Do we need to re-do aging testing if we change pouch brand?
The aging evidence belongs to the packaging system that was tested — materials, seals and configuration. A different pouch means different material and often a different sealing process, so the packaging validation and the supporting aging data are supplier responsibilities that have to be re-established rather than inherited. What does not change is the sterilizer's qualification, which is a separate record.
Is real-time aging optional if we already have accelerated data?
Real-time aging is the underlying requirement in ISO 11607-1:2019, and F1980-21 requires that real-time studies be conducted in parallel to accelerated studies and carried to the claimed shelf life. Accelerated aging is what allows a product to carry a date before the real-time study finishes, not a substitute for starting it.
What is the fastest way to check a supplier's claim?
Ask for the aging report's protocol page rather than its conclusion: standard and edition, aging temperature and humidity, Q10 value and justification, timepoints, sample configuration and test methods. If those five items are consistent, the arithmetic will be consistent too.
Sources
- ASTM F1980-21 — Standard guide for accelerated aging of sterile barrier systems and medical devices
- ASTM F1980 — current edition landing page
- ISO 11607-1:2019 — Packaging for terminally sterilized medical devices, part 1: materials, sterile barrier systems and packaging systems
- ISO 11607-2:2019 — Packaging for terminally sterilized medical devices, part 2: validation requirements for forming, sealing and assembly processes
- ASTM F88/F88M — Seal strength of flexible barrier materials
- ASTM F1929 — Detecting seal leaks in porous medical packaging by dye penetration
- ASTM D4169 — Performance testing of shipping containers and systems
- ASTM F2096 — Detecting gross leaks in packaging by internal pressurization (bubble test)
- ASTM D4332 — Conditioning containers, packages or packaging components for testing
- ASTM F17 — Standard terminology relating to primary barrier packaging
- Nelipak — Accelerated and real-time aging testing for sterile barrier packaging
- Nelson Labs — Accelerated and real-time aging tests
- Public Health Ontario (PIDAC) — Provincial guidance on cleaning, disinfection and sterilization in all health care settings
- CSA Z314:23 — Medical device reprocessing (current consolidated volume)
CliniEco Medical distributes sterilization packaging and monitoring consumables in Canada under Health Canada MDEL #35334.
0 comments